111 studies found for:    "Beta-thalassemia"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Completed Hydroxyurea to Treat Beta-Thalassemia (Cooley's Anemia)
Conditions: Beta Thalassemia;   Hemoglobinopathy
Intervention: Drug: Hydroxyurea
2 Completed Cardiac T2* in Beta-thalassemia Patients on Deferasirox Treatment
Conditions: Beta-thalassemia;   Iron Overload
Intervention: Drug: Deferasirox
3 Completed Phase I Study to Examine the Effect of Deferasirox on Renal Hemodynamics in β-thalassemia Patients With Transfusional Iron Overload
Conditions: β-thalassemia;   Transfusional Iron Overload
Intervention: Drug: Deferasirox
4 Completed Iron Balance Study of DFO and GT56-252 in Patients With Transfusional Iron Overload Secondary to Beta-Thalassemia
Condition: Beta-Thalassemia
Interventions: Drug: Deferitrin (GT56-252);   Drug: desferoxamine (DFO)
5 Completed Evaluating the Safety of G-CSF Mobilization in Individuals With Beta Thalassemia Major
Condition: Beta-Thalassemia
Intervention: Drug: Hydroxyurea
6 Completed Beta-thalassemia and Microparticles
Conditions: Thalassemia Major (TM);   Thalassemia Intermedia (TI);   Microparticles (MP)Originating From Platelets, Endothelial Cells and Monocytes
Intervention: Other: Physiopathology
7 Unknown  Evaluating the Safety and Effectiveness of Mozobil Mobilization in Adults With Beta-Thalassemia Major
Condition: Beta-Thalassemia
Intervention: Drug: Mozobil
8 Completed A Study of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional Hemosiderosis
Conditions: Beta-Thalassemia;   Hemosiderosis
Intervention: Drug: deferasirox
9 Completed Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron Overload
Conditions: Myelodysplastic Syndromes;   Beta-Thalassemia
Intervention: Drug: deferasirox
10 Recruiting A Study Evaluating the Safety and Efficacy of the LentiGlobin® BB305 Drug Product in Beta-Thalassemia Major Subjects
Condition: Beta-thalassemia Major
Intervention: Genetic: LentiGlobin® BB305 Drug Product
11 Completed Trial of HQK-1001 in Beta Thalassemia Intermedia in Lebanon
Condition: Beta Thalassemia Intermedia
Intervention: Drug: Sodium 2,2 dimethylbutyrate
12 Completed
Has Results
A 4-year Extension Study to Core 1-year Study of Iron Chelation Therapy With Deferasirox in β-thalassemia Major Pediatric Patients With Transfusional Iron Overload.
Conditions: Transfusional Iron Overload;   β-thalassemia Major;   Pediatric Rare Anemia
Intervention: Drug: Deferasirox
13 Not yet recruiting An Algorithm to Start Iron Chelation in Minimally Transfused Young Beta-thalassemia Major Patients
Condition: Beta Thalassemia Major
Intervention: Drug: Deferiprone
14 Completed
Has Results
Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration)
Conditions: Beta-thalassemia Major;   Hemosiderosis;   Iron Overload;   Rare Anemia
Intervention: Drug: Deferasirox
15 Completed Combination Therapy of Hydroxyurea With L-Carnitine and Magnesium Chloride in Thalassemia Intermedia
Condition: β-Thalassemia Intermedia
Interventions: Drug: hydroxyurea;   Drug: L-carnitine and hydroxyurea;   Drug: hydroxyurea and magnesium chloride;   Drug: hydroxyurea,L-carnitine and magnesium chloride
16 Unknown  Combined Chelation Treatment With Deferiprone and Deferoxamine in Thalassemia Major
Condition: Beta-Thalassemia
Intervention: Drug: deferiprone
17 Recruiting Safety and Efficacy of Deferasirox in Combination With Desferoxamine in β-thalassaemia Patients With Severe Cardiac Iron Overload
Conditions: Transfusion-dependent β-thalassemia Patients;   Cardiac Iron Overload
Interventions: Drug: Deferasirox;   Drug: Deferasirox + Deferoxamine
18 Completed
Has Results
An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670) in β-thalassemia Patients With Transfusional Iron Overload
Condition: Transfusional Iron Overload in β-thalassemia
Intervention: Drug: Deferasirox
19 Unknown  Genetic Factors Affecting the Severity of Beta Thalassemia
Condition: Beta Thalassemia
Intervention:
20 Not yet recruiting ACE-536 Extension Study - Beta Thalassemia
Condition: Beta-Thalassemia
Intervention: Drug: ACE-536

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years